(Source: Genentech Inc) / Media Thursday, Nov 5, 2015 South San Francisco, CA -- November 5, 2015 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that more than 45 abstracts featuring eight of its approved or investigational medicines will be presented during the 57th American Society of Hematology (ASH) Annual Meeting from December 5-8 in Orlando. The abstracts include more than 15 oral presentations across a broad range of molecular targets and combinations, as well as different clinical endpoints that Genentech is exploring in various blood diseases and lines of treatment. 'Our data at ASH this year showcase the evolution of our hematology portfolio...
↧